Trial Profile
A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 May 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ATALANTE
- 02 May 2024 This trial has been completed in Germany, according to European Clinical Trials Database record.
- 27 Mar 2024 This trial has been completed in France (Global end date: 22 Feb 2024).
- 29 Aug 2023 Results published in the Journal of Clinical Oncology